Skip to main content

Additional Articles by the Authors

Dimitrios A. Pappas, MD
Robert A. Gerber, PharmD, MA, MBA
Heather J. Litman, PhD
David Gruben, PhD
Jamie Geier, PhD
Winnie D. Hua, MS
Connie Chen, PharmD
Youfu Li, MD, MPH
Joel M. Kremer, MD
John S. Andrews, MD
Jeffrey A. Bourret, PharmD
Clinical, Review Article
The Challenge of Managing Atopic Dermatitis in the United States
Steven R. Feldman, MD, PhD; Linda S. Cox, MD; Lindsay C. Strowd, MD; Robert A. Gerber, PharmD, MA, MBA; Steven Faulkner, PharmD, MBA; Debra Sierka, PharmD; Timothy W. Smith, BA; Joseph C. Cappelleri, PhD; Mark E. Levenberg, DO
Stakeholder Perspective
Evolving Therapies for Atopic Dermatitis Will Create New Management Challenges
Gary M. Owens, MD
Read More
Clinical
The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives
Stakeholder Perspective
The Challenge of Managing Specialty Drugs for Psoriasis
Read More
Clinical
Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials
Stakeholder Perspective
Better Patient Education Needed Regarding Thromboembolic Events Risk in Patients with Cancer
Read More
Diagnosis and Treatment of Patients with Thyroid Cancer
Stakeholder Perspective
Predictive Models and Technology Present Opportunities to Support Early Diagnosis, Treatment, and Adherence to Guidelines
Read More
Clinical
New and Emerging Drugs and Targets for Type 2 Diabetes: Reviewing the Evidence
Stakeholder Perspective
Addressing Adherence a Key Challenge in the Management of Patients with Type 2 Diabetes
Read More
Clinical
Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population
Stakeholder Perspective
Treatment Decisions in the Management of Malignant Gliomas
Read More
Business
Impact of Glycemic Control on Healthcare Resource Utilization and Costs of Type 2 Diabetes: Current and Future Pharmacologic Approaches to Improving Outcomes
Stakeholder Perspective
Innovation in Patient Engagement and Management Is Critically Needed to Change Current Trends in Type 2 Diabetes
Read More
Business
Hematologic Complications, Healthcare Utilization, and Costs in Commercially Insured Patients with Myelodysplastic Syndrome Receiving Supportive Care
Stakeholder Perspective
Reconsidering the Management of Younger Patients with Myelodysplastic Syndrome
Read More
Regulatory
Quality Improvement Initiatives: The Missed Opportunity for Health Plans
Stakeholder Perspective
The Missing Quality Standard for Medication Adherence
Read More

Results 1 - 9 of 9